Dr. Eric Jonasch, MD

Dr. Jonasch practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Jonasch's NPI, 1558457028, was assigned on October 4, 2006. Dr. Jonasch graduated from McGill University Faculty of Medicine in 1992. Dr. Jonasch holds Texas license L5394.

Dr. Jonasch's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Jonasch's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Jonasch practices. Vendor and product names are available with a free account.

Medical oncology is Dr. Jonasch's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Jonasch is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Jonasch's licenses on file in 12 states: Texas, Florida, Georgia, Arizona, Louisiana, Oklahoma, Pennsylvania, Tennessee, Washington, Alabama, Mississippi and Massachusetts.

Dmand AI lists chronic anemia, multiple myeloma and prostate cancer among the conditions Dr. Jonasch treats.

CMS data shows 269 Medicare services from Dr. Jonasch across 5 procedure codes in 2024, for 166 Medicare patients. Medicare paid $25,332 for them.

CMS counts 166 Medicare patients who saw Dr. Jonasch in 2024. The largest group is 65 to 74, with 90 patients. 75% of them have cancer, and 75% have high blood pressure. 7% are also on Medicaid. Their average risk score is 2.64, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Jonasch's median patient age at 69, with 26% women.

In 2024, Dr. Jonasch wrote 533 Medicare Part D claims for 79 patients. 57% of them were for generic drugs. CMS names the drug for 407 of them, across 16 drugs with 11 or more claims each, at $4,744,536 in total drug cost. In 2023, CMS named 213 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Jonasch for performance year 2024, reported as part of a group. Dr. Jonasch accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Jonasch as offering telehealth.

Dmand AI links 282 papers to Dr. Jonasch, published from 2003 to 2025. 2016 was the busiest year, with 18. The most frequent topics are Carcinoma, Renal Cell, Kidney Neoplasms and Antineoplastic Agents. Dr. Jonasch has published most often in J Natl Compr Canc Netw. Dr. Jonasch's most frequent co-authors are Nizar M. Tannir, MD, Toni K. Choueiri, MD and Pavlos Msaouel, MD, PhD.

Dmand AI links Dr. Jonasch to 16 clinical trials, 9 of them phase 2 studies. 8 are still active or recruiting. Conditions studied include Carcinoma, Renal Cell, Kidney Neoplasms and von Hippel-Lindau Disease. M.D. Anderson Cancer Center sponsors the most, 11. Open Payments lists research payments to Dr. Jonasch that name 1 trial.

CMS Open Payments shows 341 general payments to Dr. Jonasch from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 46% of the total. Merck Sharp & Dohme Corporation paid the most, $186,699. It also lists 3 research payments totaling $1,029 from 2016 to 2023, naming 1 clinical trial.

Dmand AI lists 3 awards for Dr. Jonasch, most recently America's Top Doctors in 2014.

Dr. Jonasch graduated from McGill University Faculty of Medicine in 1992. Dr. Jonasch is a member of ASCO.

Dr. Jonasch is in network with 7 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 6. Check the plan with the practice before a visit.